HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1α gene.

Abstract
Leigh syndrome (LS) is a progressive untreatable degenerating mitochondrial disorder caused by either mitochondrial or nuclear DNA mutations. A patient was a second child of unconsanguineous parents. On the third day of birth, he was transferred to neonatal intensive care units because of severe lactic acidosis. Since he was showing continuous lactic acidosis, the oral supplementation of dichloroacetate (DCA) was introduced on 31st day of birth at initial dose of 50 mg/kg, followed by maintenance dose of 25 mg/kg/every 12 h. The patient was diagnosed with LS due to a point mutation of an A-C at nucleotide 599 in exon 6 in the pyruvate dehydrogenase E1α gene, resulting in the substitution of aspartate for threonine at position 200 (N200T). Although the concentrations of lactate and pyruvate in blood were slightly decreased, his clinical conditions were deteriorating progressively. In order to overcome the mitochondrial or cytosolic energy crisis indicated by lactic acidosis as well as clinical symptoms, we terminated the DCA and administered 0.5 g/kg/day TID of sodium pyruvate orally. We analyzed the therapeutic effects of DCA or sodium pyruvate in the patient, and found that pyruvate therapy significantly decreased lactate, pyruvate and alanine levels, showed no adverse effects such as severe neuropathy seen in DCA, and had better clinical response on development and epilepsy. Though the efficacy of pyruvate on LS will be evaluated by randomized double-blind placebo-controlled study design in future, pyruvate therapy is a possible candidate for therapeutic choice for currently incurable mitochondrial disorders such as LS.
AuthorsYasutoshi Koga, Nataliya Povalko, Koujyu Katayama, Noriko Kakimoto, Toyojiro Matsuishi, Etsuo Naito, Masashi Tanaka
JournalBrain & development (Brain Dev) Vol. 34 Issue 2 Pg. 87-91 (Feb 2012) ISSN: 1872-7131 [Electronic] Netherlands
PMID21454027 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Lactic Acid
  • Pyruvic Acid
  • Dichloroacetic Acid
  • Pyruvate Dehydrogenase (Lipoamide)
  • pyruvate dehydrogenase E1alpha subunit
  • Alanine
Topics
  • Alanine (blood)
  • Cells, Cultured
  • Child, Preschool
  • Dichloroacetic Acid (therapeutic use)
  • Electroencephalography
  • Fibroblasts (enzymology)
  • Humans
  • Lactic Acid (blood)
  • Leigh Disease (drug therapy, genetics, physiopathology)
  • Male
  • Mutation (genetics)
  • Pyruvate Dehydrogenase (Lipoamide) (genetics)
  • Pyruvic Acid (blood, cerebrospinal fluid, therapeutic use)
  • Statistics, Nonparametric

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: